ERBB2 and breast cancer: As lapatinib is used in the situation of the acquired resistance to trastuzumab in HER2-positive breast cancers clinically, we established a trastuzumab/lapatinib-dual resistant cell line (BT-474-RL2) from trastuzumab-resistant cell line (BT-474-R).